Sugi Predict

Sugi Predict / Compounds / Dimethylamine

Dimethylamine

Dimethylamine

SCHEMBL1581069

CCn1c2ccccc2c2nc3cc(C)c(C)cc3nc21.CNC

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.71
▸ ALDH1A1 P00352 7/20 0.71
▸ TSHR P16473 5/20 0.71
▸ L3MBTL1 Q9Y468 5/20 0.71
▸ USP2 O75604 4/20 0.71
▸ CASP1 P29466 4/20 0.71
▸ HSD17B10 Q99714 4/20 0.71
▸ KDM4E B2RXH2 4/20 0.71
▸ CASP7 P55210 3/20 0.71
▸ NPC1 O15118 3/20 0.71
▸ HCRTR1 O43613 1/20 0.71
▸ TP53 P04637 1/20 0.71
▸ KMT2A Q03164 5/20 0.67
▸ TDP1 Q9NUW8 3/20 0.67
▸ MEN1 O00255 3/20 0.67
▸ GLA P06280 1/20 0.67
▸ ALOX12 P18054 1/20 0.67
▸ GAA P10253 3/20 0.60
▸ HTT P42858 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16084877 0.84 TSHR (0.78) MAPTALDH1A1TSHRL3MBTL1USP2
SCHEMBL5524713 0.84 MAPT (1.00) MAPTALDH1A1TSHRL3MBTL1USP2
Dimethylamine SCHEMBL9706094 0.83 MAPT (0.51) MAPTALDH1A1TSHRL3MBTL1USP2
SCHEMBL9436911 0.80 ALDH1A1 (0.77) MAPTALDH1A1TSHRL3MBTL1USP2
Dimethylamine SCHEMBL9706176 0.80 MAPT (0.67) MAPTALDH1A1TSHRL3MBTL1USP2
SCHEMBL16084809 0.78 TSHR (0.57) MAPTALDH1A1TSHRL3MBTL1USP2
SCHEMBL1581068 0.78 POLB (0.61) MAPTALDH1A1TSHRL3MBTL1USP2
SCHEMBL30297107 0.78 POLB (0.61) MAPTALDH1A1TSHRL3MBTL1USP2
SCHEMBL1611193 0.77 ALDH1A1 (0.59) MAPTALDH1A1TSHRL3MBTL1USP2
Dimethylamine SCHEMBL9706172 0.76 MAPT (0.92) MAPTALDH1A1TSHRL3MBTL1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9789107-B2 Pharmaceutical formulation comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-B)quinoxaline VIRONOVA HERPES AB (SE) 2017-10-17 — — US claimed
US-20150320746-A1 PHARMACEUTICAL FORMULATION COMPRISING 2,3-DIMETHYL-6-(N,N-DIMETHYLAMINOETHYL)-6H-INDOLO-(2,3-B)QUINOXALINE VIRONOVA HERPES AB (SE) 2015-11-12 — — US claimed
WO-2022002898-A1 6H-INDOLO(2,3-B)QUINOXALINE DERIVATIVES USEFUL IN THERAPY IN PARTICULAR IN A VIRUS INFECTION VIRONOVA MEDICAL AB (SE) 2022-01-06 — — WO disclosed
US-20160031889-A1 ANTIVIRAL INDOLO[2,3-B]QUINOXALINE VIRONOVA HERPES AB (SE) 2016-02-04 — — US disclosed
EP-2970292-A1 ANTIVIRAL INDOLO[2,3-B]QUINOXALINE Vironova Herpes AB (SE) 2016-01-20 — — EP disclosed
WO-2014140321-A1 ANTIVIRAL INDOLO[2,3-B]QUINOXALINE VIRONOVA AB (SE) 2014-09-18 — — WO disclosed
US-8084453-B2 Alkyl substituted indoloquinoxalines OXYPHARMA AB (SE) 2011-12-27 — — US disclosed
US-8076341-B2 Compounds and use thereof VIRONOVA AB (SE) 2011-12-13 — — US disclosed
EP-1976853-B1 NOVEL COMPOUNDS AND USE THEREOF VIRONOVA AB (SE) 2011-04-20 — — EP disclosed
US-20110086859-A9 ALKYL SUBSTITUTED INDOLOQUINOXALINES OXYPHARMA AB (SE) 2011-04-14 — — US disclosed
EP-1756111-B1 ALKYL SUBSTITUTED INDOLOQUINOXALINES OXYPHARMA AB (SE) 2010-03-31 — — EP disclosed
US-20100009999-A1 ALKYL SUBSTITUTED INDOLOQUINOXALINES OXYPHARMA AB (SE) 2010-01-14 — — US disclosed
US-20090318458-A1 NOVEL COMPOUNDS AND USE THEREOF VIRONOVA HERPES AB (SE) 2009-12-24 — — US disclosed
US-7589093-B2 2,3-Dimethylindolo[2,3-b]quinoxaline-6-yl-acetamide; 9-Chloro-2,3-dimethyl-6-(aminoethylamino-2-oxoethyl)-6H-indolo[2,3-b]quinoxaline; autoimmune diseases OXYPHARMA AB (SE) 2009-09-15 — — US disclosed
EP-1756111-A1 ALKYL SUBSTITUTED INDOLOQUINOXALINES Oxypharma AB (SE) 2007-02-28 — — EP disclosed
US-20050288296-A1 Alkyl substituted indoloquinoxalines CYXONE AB, 559020-5471 (SE) 2005-12-29 — — US disclosed
WO-2005123741-A1 ALKYL SUBSTITUTED INDOLOQUINOXALINES OXYPHARMA AB (SE) 2005-12-29 — — WO disclosed
EP-0238459-B1 SUBSTITUTED INDOLOQUINOXALINES Lundblad, Leif (SE) 1992-04-15 — — EP disclosed
EP-0238459-A1 Substituted indoloquinoxalines Lundblad, Leif (SE) 1987-09-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086859-A9 ALKYL SUBSTITUTED INDOLOQUINOXALINES HRH4, HRH3, NR4A1 MAPT 4647/4885ALDH1A1 3537/4885TSHR 32/4885
US-20100009999-A1 ALKYL SUBSTITUTED INDOLOQUINOXALINES HRH4, HRH3, NR4A1 MAPT 4647/4885ALDH1A1 3537/4885TSHR 32/4885
US-20150320746-A1 PHARMACEUTICAL FORMULATION COMPRISING 2,3-DIMETHYL-6-(N,N-DIMETHYLAMINOETHYL)-6H-INDOLO-(2,3-B)QUINOXALINE NME2, S100A10, DSG1 MAPT 3336/4885ALDH1A1 4261/4885TSHR 4739/4885
US-20160031889-A1 ANTIVIRAL INDOLO[2,3-B]QUINOXALINE IRF3, IFNG, IDO1 MAPT 748/4885ALDH1A1 2004/4885TSHR 4726/4885
US-20090318458-A1 NOVEL COMPOUNDS AND USE THEREOF YAP1, BID, BRD4 MAPT 1205/4885ALDH1A1 3051/4885TSHR 2937/4885
US-20050288296-A1 Alkyl substituted indoloquinoxalines HRH4, HRH3, NR4A1 MAPT 4647/4885ALDH1A1 3537/4885TSHR 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.